Smith & Nephew plc (LON:SN) Receives Average Rating of “Hold” from Analysts

Smith & Nephew plc (LON:SN) has earned an average rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is GBX 1,381.33.

SN has been the subject of several recent research reports. Panmure Gordon reissued a “hold” rating and issued a GBX 1,200 price target on shares of Smith & Nephew in a research note on Tuesday, December 9th. Berenberg Bank reiterated a “hold” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Friday, January 23rd. Royal Bank Of Canada lowered shares of Smith & Nephew to a “sector perform” rating and dropped their price target for the stock from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Citigroup raised their price target on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th.

Smith & Nephew Price Performance

Shares of SN stock opened at GBX 1,371.50 on Friday. The business has a fifty day moving average price of GBX 1,258.93 and a 200-day moving average price of GBX 1,303.60. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The firm has a market cap of £15.04 billion, a price-to-earnings ratio of 49.38, a P/E/G ratio of 0.46 and a beta of 0.62.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.